|
|
³¯Â¥ |
2010-12-02 |
|
|
Á¦¸ñ |
Scrip Intelligence |
|
|
³»¿ë |
Scrip May 25th 2007
Headlines *Amgen to appeal CHMP's negative stance on Vectibix *BTG comes through cost cuts with extra cash for research & development *China edges forward on intellectual property in US talks *CHMP gives green light to Roche's Mircera *Danish agency rules out generic prescription *Disgruntled Apotex finally launches its generic Norvasc *EMEA (European Medicines Agency) restricts bicalutamide 150mg to high-risk patients *GlaxoSmithKline set to launch research & development operations in China *Ixico raises £2.44 million in investments *Jobs go as CV Therapeutics sticks with Ranexa *KV's Clindesse email alert overstates efficacy FDA says *MEPs say no to EU directive on health services *No counterfeits in French supply chain says regulator *Parallel trade blamed for UK counterfeit Zyprexa *Pharma wants agencies to conduct joint manufacturing inspections *Pharmaceutical spending on the rise in Spain: *Tercica's Increlex among latest EU positive opinions *US FDA panel to review Evista for reducing breast cancer risk: *US FDA warning Enzon over Abelcet promotion *US growth for Abilify drives Otsuka *US rejects Brazilian resolution on access to medicines *Velcade/Doxil combination approved for multiple myeloma in the US
°ü·ÃURL : http://www.scrippharma.com
|
|
|